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UKAbstract The United Kingdom (UK) uveal melanoma guideline development group used an
evidence based systematic approach (Scottish Intercollegiate Guidelines Network (SIGN)) to
make recommendations in key areas of uncertainty in the ﬁeld including: the use and effective-
ness of new technologies for prognostication, the appropriate pathway for the surveillance of
patients following treatment for primary uveal melanoma, the use and effectiveness of new
technologies in the treatment of hepatic recurrence and the use of systemic treatments. The
guidelines were sent for international peer review and have been accredited by NICE. A(http://
cuMel
P. Nathan et al. / European Journal of Cancer 51 (2015) 2404–2412 2405summary of key recommendations is presented. The full documents are available on the
Melanoma Focus website.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Aim of the guideline
The aim of these guidelines is to optimise patient care
by providing recommendations based on the best avail-
able scientiﬁc evidence. These guidelines should assist
the planning of patient care and provide an indication
of the likely clinical outcomes, as well as facilitating
patient counselling and informed decision-making.
Where adequate evidence is lacking, the guideline devel-
opment group (GDG) has, where possible, arrived at an
expert consensus. The Group recognises, however, that
each patient is an individual. These guidelines should
therefore neither be prescriptive nor dictate clinical care;
however, where care signiﬁcantly diﬀers from the guide-
lines, it should be justiﬁable. Our review also identiﬁes
gaps in current evidence, thereby deﬁning scope for fur-
ther research and audit.
The GDG reviewed the evidence, where available, for
the key areas of uncertainty in the ﬁeld, which include:
 The use and eﬀectiveness of new technologies such as
cytogenetics/genetic analysis for prognostication.
 The appropriate pathway for the surveillance of
patients following treatment for primary uveal
melanoma.
 The use and eﬀectiveness of new technologies in the
treatment of hepatic recurrence.
 The use of systemic treatments.1.2. Background
Uveal melanoma has an incidence of approximately
2–8 per million per year in Caucasians [23] these
tumours are even less common in races with brown eyes.
More than 90% involve the choroid, the remainder being
conﬁned to iris and ciliary body. Both sexes are aﬀected
in equal numbers [12,5]. The age at presentation peaks
at approximately 60 years, except for iris melanomas,
which usually present at a younger age [5,18]. Risk fac-
tors for uveal melanoma include light-coloured irides
[15], congenital ocular melanocytosis [19], melanocy-
toma [14] and neuroﬁbromatosis [19]. The role of sun-
light is uncertain [20]. Familial cases are very rare but
some patients may have familial atypical mole and mel-
anoma syndrome; these cases require monitoring by a
dermatologist as they are also at risk of cutaneous mel-
anoma [22]. Rare families carry germline mutations of
the BAP1 gene on chromosome 3, which predisposesthem to develop uveal melanoma, mesothelioma and
other cancers [2].
Staging for uveal melanoma follows the American
Joint Committee on Cancer (AJCC)
Tumour-Node-Metastasis (TNM) staging system for
eye cancer [7,8]. Outcomes for patients with uveal mela-
noma vary widely, but for patients with early tumours
they are excellent. In a cohort of 8033 patients, the
10-year metastatic rate for a 1-mm-thick uveal mela-
noma was 5%, for a 2-mm-thick uveal melanoma it
was 10%, and that for a 6-mm-thick uveal melanoma
it was 30% [16,17]. When grouping 7621 uveal melano-
mas into small (0–3 mm thick, 29.8%), medium (3.1–
8 mm thick, 49%) or large (>8 mm thick, 20.9%)
tumours, the 10-year rates of detecting metastases were
11.5%, 25.5% and 49.2% respectively [16,17].
An online tool, the Liverpool Uveal Melanoma
Prognosticator Online (LUMPO), has been developed
and is freely available. It generates an all-cause mortal-
ity curve according to age, sex, AJCC TNM size cate-
gory (based on basal tumour diameter and tumour
height), ciliary body involvement, melanoma cytomor-
phology, closed loops, mitotic count, chromosome 3 loss
and presence of extraocular spread (www.ocularme-
lanomaonline.com) [4].
Cytogenetic and molecular genetic features of the
uveal cells have been demonstrated to have strong prog-
nostication value in uveal melanoma. The most striking
abnormality in uveal melanoma is the complete or par-
tial loss of chromosome 3. Other common genetic
abnormalities of uveal melanoma include loss on the
short arm (p) of chromosome 1, and gains on 6p and
8q (see review, [3]. The above-mentioned chromosomal
alterations in primary UM are clinically relevant
because of their correlation with the risk of metastatic
death. Chromosome 3 loss is associated with a
reduction of the 5-year survival probability from
approximately 100% to about 50%. Similarly, chromo-
some 8 gains and loss of chromosome 1 signiﬁcantly
correlate with reduced survival [21,13]. Conversely,
gains in chromosome 6p correlate with a good progno-
sis, suggesting this aberration may have a functionally
protective eﬀect.
The natural history of uveal melanoma is charac-
terised by the frequent development of metastases and
patients develop metastatic disease at any time from
the initial diagnosis of the primary to several decades
later [9,6,11]. The risk of metastatic relapse for an indi-
vidual varies greatly dependent on primary tumour
characteristics and genetic alterations.
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The median survival from the time of the development
of distant metastatic disease is 2–12 months and 1-year
survival 10–15%. This range reﬂects a number of prog-
nostic factors including the burden of metastatic disease
and the eﬀect of metastatic screening programmes [1].
The liver is the most common site for uveal mela-
noma metastases, with 50% of patients having
liver-only disease, and 90% of those with metastases
elsewhere (bowel, bone, lung and lymph nodes) also
having liver metastases [10,24]. Liver disease is usually
multifocal, often in a miliary distribution, but some
patients may develop isolated metastases, enabling sur-
gical removal. Liver involvement is the cause of death
in most patients with metastatic uveal melanoma [24].
Most patients die from parenchymal liver failure, but
obstructive jaundice may result from liver metastases
compressing the common hepatic or intrahepatic ducts
or, less commonly, from porta hepatis nodal disease
compressing the extrahepatic duct.
1.3. Strengths and limitations of the evidence
Due to the rarity of uveal melanoma and associated
poor prognosis, there is limited clinical evidence guiding
the optimal treatment of metastatic disease. Most
reports in the literature are of small case series of ten
or fewer patients. Larger non-randomised studies were
scrutinised carefully for a survival bias as mortality is
so high. With regard to treatment of primary tumours,
each United Kingdom (UK) centre tends to have speciﬁc
areas of interest and no centre oﬀers all potential treat-
ment options. Whilst the centres compare their results in
regular meetings, there are no randomised comparative
trials (RCT) from the UK. The COMS study
(Collaborative Ocular Melanoma Study (http://www.
jhu.edu/wctb/coms/) in the US has provided a valuable
source of data; however, overall, the limitations of the
evidence base in the literature are considerable.
1.4. Risks versus beneﬁts
In weighing up the risks and beneﬁts of any interven-
tion, the guideline development group (GDG) has con-
centrated on an analysis of clinical beneﬁt and, where
appropriate, toxicity. It has not performed any
cost-eﬀectiveness analyses as this falls outside the remit
of these guidelines.
2. Methods
The guideline was convened under the UK
Melanoma Study Group, a precursor of Melanoma
Focus, now a national charity with a professional core
membership undertaking research and education in the
ﬁeld of melanoma and skin cancers. The guideline and
supporting documentation are available on theMelanoma Focus website http://melanomafocus.com/
activities-2/ocular-melanoma-project/).
The number of health professionals who provide care
to patients with uveal melanoma in the UK is relatively
small and the aim was to reﬂect the views of a signiﬁcant
proportion of these within the GDG. There are three
ocular oncology referral centres in England that deliver
primary treatment (surgery) for patients with uveal mel-
anoma (Liverpool, London and Sheﬃeld) whilst a hand-
ful of other centres have a specialist interest in the
treatment of uveal melanoma metastatic disease. GDG
members were selected to represent these centres as well
as the professions involved in delivering care. In addi-
tion to the thirteen health professionals, including a trai-
nee, there were originally three patient representatives
(one of whom resigned for personal reasons) and a pro-
ject manager on the GDG. The guideline was started in
February of 2012, with the ﬁrst Guideline Development
Group meeting held in April 2012; in all, seven GDG
meetings were held over a period of two years. GDG
members completed a Declaration of Interest form prior
to the ﬁrst meeting, which was subsequently updated.
All interests were declared at the ﬁrst meeting and it
was agreed that members who had a commercial interest
in a drug or technology under discussion could remain
in the room and answer questions from GDG members
but could not participate in the discussion or the formu-
lation of recommendations.
As the clinical area and the associated body of litera-
ture is small, it was decided to do one all-encompassing
initial literature search and then to sift references for
each question within the database. The original search
was carried out by the Royal College of Physicians on
27 March 2012, with the search repeated to identify
new evidence on 21 June 2013 and again 16 April
2014. Questions were drafted based on inputs from
GDG members. Subgroups of content experts on the
GDG worked on each topic, agreeing the criteria for
including papers, then appraising and extracting refer-
ences using a ‘Scottish Intercollegiate Guidelines
Network’ (SIGN)) checklist as a guide. However as most
of the evidence consisted of small case series, for some
questions additional criteria were applied to appraise
quality, in particular whether the case series included
patients from more than one centre. The sub-groups
were supported and advised by a guideline methodolo-
gist. The subgroups presented the evidence review and
extraction tables to the full GDG at the group’s
meetings. The full GDG discussed the evidence and for-
mulated evidence statements and recommendations.
A great deal of work was done electronically and follow-
ing update search revisions all GDG members were sent
several drafts of chapters for comment.
The evidence was appraised and extracted into tables;
see Appendix A, which includes many references that
were reviewed but not included in the ﬁnal document.
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able in the document entitled Uveal Melanoma
Guideline Development Methodology at http://me-
lanomafocus.com/activities-2/the-uveal-melanoma-na-
tional-guidelines-project/.
2.1. Levels of evidence
The grading of the evidence is based on the Scottish
Intercollegiate Guidelines Network (SIGN) grading sys-
tem 1999–2012 http://www.sign.ac.uk/guidelines/full-
text/50/annexoldb.html.1++ High quality meta-analyses, systematic reviews of
RCTs, or RCTs with a very low risk of bias.1+ Well-conducted meta-analyses, systematic
reviews, or RCTs with a low risk of bias.1 Meta-analyses, systematic reviews, or RCTs with
a high risk of bias.2++ High quality systematic reviews of case control or
cohort or studies. High quality case control or
cohort studies with a very low risk of
confounding or bias and a high probability that
the relationship is causal.2+ Well-conducted case control or cohort studies with
a low risk of confounding or bias and a moderate
probability that the relationship is causal.1 Case control or cohort studies with a high risk of
confounding or bias and a signiﬁcant risk that the
relationship is not causal.3 Non-analytic studies, e.g. case reports, case series.
4 Expert opinion.2.2. Grade of recommendations
The grading of recommendations is also based on
SIGN 199-2012:A At least one meta-analysis, systematic review, or
RCT rated as 1++, and directly applicable to the
target population; or A body of evidence
consisting principally of studies rated as 1+,
directly applicable to the target population, and
demonstrating overall consistency of results.B A body of evidence including studies rated as
2++, directly applicable to the target population,
and demonstrating overall consistency of results;
or Extrapolated evidence from studies rated as
1++ or 1+.C A body of evidence including studies rated as 2+,
directly applicable to the target population and
demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 2++.D Evidence level 3 or 4; or Extrapolated evidence
from studies rated as 2+.GPP Recommended best practice based on the clinical
experience of the guideline development group.3. Recommendationsf Cancer 51 (2015) 2404–2412 24073.1. Patient Choice and Shared decision-making
1. All specialist surgical ocular oncology multidisci-
plinary teams (MDTs) should collaborate to produce
an information leaﬂet on the options available
nationally. [GPP]
2. All available procedural and treatment options, local,
national and international should be discussed with
the patient. [GPP]
3. The risks andbeneﬁts of any procedures and treatments
being considered should be fully discussed with the
patient, including their impact on quality of life. [GPP]3.2. Service conﬁguration
1. Supra-regional specialist multi-disciplinary teams
(MDT), using a network model, should be estab-
lished that promote a coordinated approach for the
care and follow-up of all patients with uveal mela-
noma. For advanced disease, a specialist oncology
MDT should consist of a medical or clinical oncolo-
gist, an interventional radiologist, a diagnostic radiol-
ogist a histopathologist, a liver surgeon and a clinical
nurse specialist, all with experience in treating uveal
melanoma and with direct links to ocular surgical
oncology centres. The MDT should make recommen-
dations on an individual patient’s tumour staging and
management, and have available all treatments and
trials locally or by referral. [GPP]
2. Any molecular testing should be carried out within an
accredited molecular pathology laboratory with
appropriate quality assurance in place to provide
the required standards and experienced interpretation
of the diagnostic test, in compliance with national
requirements. [GPP]
3. A national register, based on a standardised minimum
data set, should be established where details of every
patient with a diagnosis of uveal melanoma are entered,
with follow-up data collected at least annually. [GPP]3.3. General guidance
1. All local recurrences of the primary uveal melanoma
should be reported to the surgical ocular oncology
centre where treatment for the primary tumour took
place. [GPP]
2. All Optometrists and Ophthalmologists should
receive training in the recognition of uveal mela-
noma, in order to allow earlier detection and timely
referral of patients with uveal melanoma. [GPP]
3. Each surgical ocular oncology centre should audit
their results and share them nationally. [GPP]
4. The suspected diagnosis of uveal melanoma by the
referring clinician should follow the same pathways
as for any other suspected cancer. The ocular
en
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2408 P. Nathan et al. / European Journal of Cancer 51 (2015) 2404–2412oncology centre should be notiﬁed within 48 hours of
presentation and the patient seen by the specialist
within two weeks. Grade C
5. Suspicious lesions or lesions diagnosed as uveal
melanoma should be referred to a consultant surgical
ocular oncologist in one of the surgical oncology cen-
tres for ocular malignancies. Grade D
6. Specimens should be reported by an ophthalmic
pathologist within a specialist centre. [GPP]
7. All patients with a new diagnosis of uveal melanoma
should be oﬀered referral to a medical or clinical oncol-
ogist with a specialist interest in the disease. [GPP]
8. Patients should be informed about and recruited into
clinical trials wherever possible. [GPP]
9. Patients should be oﬀered the opportunity to partici-
pate in uveal melanoma speciﬁc research. With patient
consent, samples should be taken surplus to diagnostic
requirements and stored in an ethically-approved
quality biobank for research purposes. [GPP]O
u
tc
o
m
es
C
o
m
p
li
ca
ti
o
n
s
C
o
m
m
G
o
o
d
lo
ca
l
tu
m
o
u
r
co
n
tr
o
l
L
o
ss
o
f
vi
si
o
n
T
u
m
o
u
r
re
cu
rr
en
ce
D
o
se
ad
ju
st
G
o
o
d
lo
ca
l
tu
m
o
u
r
co
n
tr
o
l
L
o
ss
o
f
vi
si
o
n
L
o
ss
o
f
th
e
ey
e
fr
o
m
n
eo
va
sc
u
la
r
gl
au
co
m
a
T
u
m
o
u
r
re
cu
rr
en
ce
N
o
t
a
u
n
it
s
G
o
o
d
lo
ca
l
tu
m
o
u
r
co
n
tr
o
l
L
o
ss
o
f
vi
si
o
n
R
ad
ia
ti
o
n
re
la
te
d
co
m
p
li
ca
ti
o
n
s
T
u
m
o
u
r
re
cu
rr
en
ce
N
o
t
a
u
n
it
s3.4. Primary management
3.4.1. Pre-operative investigations
1. Make a diagnosis of uveal melanoma using ophthal-
moscopy, fundus photography and conventional ocu-
lar ultrasound. Grade A
2. Ciliary body melanoma should be imaged with
UltrasoundBiomicroscopy (UBM) or anterior segment
Optical Coherence Tomography (OCT). Grade D
3. If the clinical diagnosis is uncertain following the
above-mentioned techniques then diagnostic biopsy
should be considered and balanced against potential
risks of the procedure. [GPP]
4. Fine needle aspiration biopsy can be performed either
with a direct transcleral approach or using a transvit-
real approach. Grade DU
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y3.4.2. Staging before primary treatment
1. A decision on staging should be made based on the
individual circumstances of the patient, but staging
should not delay the primary management of the
tumour. [GPP]
2. Staging should be considered in the following
circumstances:
 The patient is at particularly high risk because of the
clinical features of their presentation.
 The patient is particularly anxious and requires reas-
surance. [GPP]at
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rg3.4.3. Treatment of the primary tumour
1. Patients should be informed that there is no proven
survival advantage between any of the oﬀered modal-
ities. Grade A
2. Treat patients using table belowT
re
R
a
B
ra 1
P
ro
S
te
Phototherapy
Transpupillary
thermotherapy
Local recurrence and of
adjuvant therapy of
uveal melanoma
Improves
local
tumour
control
Loss of vision Extraocular
tumour recurrence
Very occasionally used by some centres
for small melanoma nasal to the optic
disc. When considering preservation of
vision, for example in a one eyed
patient; as it avoids radiotherapy
complications. However, it is no longer
recommended routinely as a sole
primary treatment.
Grade C
Photodynamic therapy Small melanoma Uncertain Tumour recurrence Avoids radiotherapy complications New
treatment option not widely used for
uveal melanoma. This is an
experimental treatment.
Grade D
Surgery
Exoresection ± plaque Medium to large
melanoma with a
narrow basal diameter
Variable Retinal detachment Loss of
vision Loss of the eye
Tumour recurrence Risk of
orbital dissemination of
tumour
Rarely performed in the UK. Only
performed in limited centres. Always
performed with brachytherapy to reduce
the risk of recurrence
Grade C
Endoresection ± radiotherapy Medium-sized uveal
melanoma. Toxic
tumour syndrome post
PBR
Variable Transient intraocular
haemorrhage; Rarely
tumour seeding
Only performed in limited centres in the
UK
Grade D
Enucleation Large uveal melanoma
Melanoma associated
with NVG ± extensive
retinal detachment
100% local
tumour
control if
completely
excised
Socket related complications
Orbital recurrence
Cosmetic results are reasonably good
with an orbital implant and artiﬁcial eye
Grade A
Exenteteration Large extra-ocular
extension after uveal
melanoma
100% local
tumour
control if
completely
excised
Orbital recurrence Rarely performed in the UK. Grade D
* = as deﬁned by (Diener-West, Hawkins et al., 1992)
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1. Patients treated with plaque brachytherapy, proton
beam radiotherapy or stereotactic radiotherapy
should be monitored for tumour regression inten-
sively over the ﬁrst two years following treatment.
Long-term follow up intervals depend on the
response of the tumour to brachytherapy and the
radiotherapy complications experienced. [GPP]
3.5. Prognostication
3.5.1. Prognostic factors/tool
1. Prognostic factors of uveal melanoma are
multi-factorial and include clinical, morphological
and genetic features. The following features should
be recorded:
 Age
 Gender
 Tumour location
 Tumour height
 Tumour Largest basal diameter
 Ciliary body involvement
 Extraocular melanoma growth (macroscopic)
The following features should be recorded if tissue is
available:
 Cell type (modiﬁed Callender system)
 Mitotic count (number/40 high power ﬁelds in H&E
stained sections)
 Presence of extravascular matrix patterns (particu-
larly closed connective tissue loops; enhanced with
Periodic acid Schiﬀ staining). Grade A
 Presence of extraocular melanoma growth (size, pres-
ence or absence of encapsulation). [GRADE A]3.5.2. Prognostic biopsy
1. There should be a fully informed discussion with all
patients, explaining the role of biopsy including the
beneﬁts and risks. The discussion should include:
 Risk of having the biopsy
 Limitations of the investigation
 Beneﬁts for future treatments (including possible
recruitment to trials)
 Impact on quality of life
 Recruitment to trials
 Follow-up. [GPP]
2. The minimum dataset for uveal melanoma from the
Royal College of Pathology should be recorded.
http://www.rcpath.org/publications-media/publica-
tions/datasets/uveal-melanoma.htm. Grade D3. Tests for novel serological biomarkers should only
be used within clinical trials or research pro-
grammes. [GPP]
4. Consider collecting molecular genetic and/or cyto-
genetic data for research and prognostication pur-
poses where tumour material is available and
where patient consent has been obtained as part
of an ethically approved research programme.
[GPP]
5. Use of the current (i.e. 7th) Edition of the TNM
staging system for prognostication is highly rec-
ommended. Grade A
6. Use of multifactorial prognostication models
incorporating clinical, histological, immunohisto-
chemical and genetic tumour features – should be
considered. Grade D3.6. Surveillance
1. Prognostication and surveillance should be led by a
specialist multidisciplinary team that incorporates
expertise from ophthalmology, radiology, oncology,
cancer nursing and hepatic services. [GPP]
2. Prognostication and risk prediction should be based
on the best available evidence, taking into account
clinical, morphological and genetic cancer features.
[GPP]
3. All patients, irrespective of risk, should have a holis-
tic assessment to discuss the risk, beneﬁts and conse-
quences of entry into a surveillance programme. The
discussion should consider risk of false positives, the
emotional impact of screening as well as the fre-
quency and duration of screening. An individual plan
should be developed. [GPP]
4. Patients judged at high-risk (see Section Error!
Reference source not found.) of developing metas-
tases should have 6-monthly life-long surveillance
incorporating a clinical review, nurse specialist sup-
port and liver-speciﬁc imaging by a non-ionising
modality. [GPP]
5. Liver function tests alone are an inadequate tool for
surveillance. Grade C3.7. Metastatic disease
3.7.1. Staging
1. Patients should have whole body staging (chest,
abdomen and pelvis) with CT scan or PET CT.
Grade D
2. Brain imaging should not be carried out in the
absence of symptoms. [GPP]
3. Patients who have symptomatic bony pain should
have a bone scan to assess the presence of bony dis-
ease. [GPP]
P. Nathan et al. / European Journal of Cancer 51 (2015) 2404–2412 24114. Contract enhanced MRI with diﬀusion weight imag-
ing should be used to stage liver disease when assess-
ing operability. Grade D
5. Contrast-enhanced CT scan should be used to stage
extrahepatic disease. Grade D
3.7.2. Prognostic method
1. This minimum data set should be collected for all
patients with systemic disease (Stage IV) for future
validation:
 Metastatic Tumour Burden (site, diameter and
number),
 LDH
 ALP
 GGT
 Bilirubin
 Presence or absence of ascites
 Gender
 Age
 Performance status,
 DFS following deﬁnitive primary therapy. [GPP]
2. A tissue sample should be taken to conﬁrm the
diagnosis of metastatic uveal melanoma unless
contraindicated. [GPP]
3. Curative (R0) resection is the most important pos-
itive prognostic factor following liver resection.
[GPP]
3.7.3. Management of systemic and oligometastatic-
extrahepatic disease
1. Patients should be considered for clinical trials wher-
ever possible and be informed of available trial
options at other centres.[GPP]
2. Patients with good performance status (PS 0-2) who
decline trials or for whom no suitable clinical trials
are available should be oﬀered systemic treatments
and managed in specialist centres with appropriate
oncology expertise in uveal melanoma. [GPP]
3. Specialist centres should be involved in treatment
decisions and review, but a patient may prefer to
receive supportive care and systemic treatment
locally. [GPP]
4. Patients with liver predominant disease should be
considered for regional therapy. Grade D
5. Loco-regional treatment for the management of oli-
gometastatic disease (i.e. when metastases are limited
to a single or limited number of organs) should be
considered. This may include surgery, stereotactic
treatment or other forms of ablation. [GPP]
6. Ipilimumab can be oﬀered in the UK following NICE
approval of this drug for use in melanoma
generically.3.7.4. Management of liver metastases
1. For patients with technically resectable disease,
assessment for curative intent hepatic resection
should be oﬀered. Grade D
2. Pre-operative diagnostic laparoscopy should be per-
formed in patients with radiologically resectable liver
metastases, as many of these patients will have a mil-
iary pattern of disease. Grade D
3. Regional or systemic treatments may be considered in
patients with liver dominant disease where resection
is not suitable. [GPP]3.7.5. Surveillance following liver treatment
1. Patients treated with curative intent should be fol-
lowed with regular (3–4 monthly) hepatic MRI and
CT of chest, abdomen and pelvis. [GPP]
2. Patient outcomes for this selected group should be
collected centrally and prospectively. [GPP]Conﬂict of interest statement
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